Fewer than 10% of patients eligible to benefit from weight-loss injections including Wegovy can access them, states the World Health Organization as it issues its first guidance on the medications.
Given in excess of 1,000,000,000 people worldwide now obese, it is advocating for broader and more equitable availability to GLP-1 medication.
According to forecasts, over two billion will be obese by 2030 without intervention.
"The new guidelines recognises that excess weight is a long-term condition that can be addressed with thorough and lifelong treatment," said its chief Tedros Adhanom Ghebreyesus.
High costs, constrained manufacturing, and supply-chain constraints are significant hurdles to broad availability to the jabs that can assist patients in reducing substantial weight, explains the body.
Weight-Loss Drug Supply Crisis
Even in the current best projected case, the supply of these medications might only reach approximately 100 million people – less than 10% of those who need them, as stated by the health organization.
The recommendation urges governments and firms to increase access, by approaches like voluntary licensing.
The intellectual property rights on semaglutide – the main ingredient of a leading brand – is due to expire in several countries in 2026.
How Obesity Jabs Function
The injections imitate a body's own hormone to reduce digestion speed, suppress the appetite and enhance the sense of being full so people eat less.
Patients commonly begin shedding pounds after several weeks of commencing the weekly injections.
Evidence indicates patients may put most of the weight back on a year later of halting the medication, when their typical hunger return.
To be overweight or obese increases your likelihood for developing health problems, including type 2 diabetes, cardiovascular issues, brain attack, and some cancers.
Obesity impacts people in every country and was associated with over three and a half million fatalities worldwide in 2024, according to the health agency.
